Suberoylanilide hydroxamic acid (SAHA), a famous histone deacetylase (HDAC) inhibitor, has been utilized in clinical treatment for cutaneous T-cell lymphoma. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.